iSTAR Medical Continues Market Expansion with First MINIject® Surgeries in the UK
March 28, 2022 02:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical Continues Market Expansion with First MINIject® Surgeries in the UK UK patients and surgeons now able to benefit from the only commercially available MIGS device...
Endoprosthesis Market Size Worth USD 45,134.19 Million by 2027 at 11.58% CAGR - Report by Market Research Future (MRFR)
August 26, 2021 11:00 ET
|
Market Research Future
New York, US, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Endoprosthesis Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Endoprosthesis Market...
Brain Implant Market Value Predicted To Reach US$ 7,895.4 Million By 2027 Covering Pre and Post COVID-19 Market Analysis: Acumen Research And Consulting
April 21, 2021 12:19 ET
|
Acumen Research and Consulting
LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) -- The Global Brain Implant Market is expected to grow at a CAGR of around 9.2% from 2020 to 2027 and reach the market value of over US$ 7,895.4 Mn by...
ObsEva Announces Third Quarter 2019 Financial Results
November 07, 2019 01:10 ET
|
ObsEva SA
– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast...
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
October 31, 2019 02:00 ET
|
ObsEva SA
FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the...
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
September 03, 2019 01:00 ET
|
ObsEva SA
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial...
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
July 17, 2019 12:00 ET
|
ObsEva SA
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ:...
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
June 19, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
June 04, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
April 29, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...